STOCK TITAN

Trevi Therapeutics: Frazier reports 5.5% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. (TRVI) is the issuer in an amended ownership report: Frazier Life Sciences Public Fund, L.P. reports shared voting and dispositive power over 7,883,659 common shares, or 5.5%. Frazier Life Sciences X, L.P. reports 365,909 shares (0.3%), and Frazier Life Sciences XI, L.P. reports 1,289,579 shares (0.9%). The percentages are based on 142,475,841 shares outstanding as of July 31, 2026.

The reported share amounts exclude prefunded warrants held by the three funds: respectively, warrants to purchase 10,331,265, 1,458,294, and 2,459,389 shares. Each warrant position is subject to a limit preventing exercise if it would cause the holder, together with affiliates or persons acting as a group, to beneficially own more than 9.99% of shares outstanding immediately after exercise. The FLS X position is also reported by its general-partner entities and members James N. Topper and Patrick J. Heron.

Frazier Life Sciences Public Fund common shares 7,883,659 shares 5.5% beneficial ownership; shared voting and dispositive power
Frazier Life Sciences X common shares 365,909 shares 0.3% beneficial ownership; held directly by Frazier Life Sciences X, L.P.
Frazier Life Sciences XI common shares 1,289,579 shares 0.9% beneficial ownership; held directly by Frazier Life Sciences XI, L.P.
Common shares outstanding 142,475,841 shares As of July 31, 2026; basis for the reported ownership percentages
Public Fund prefunded warrants 10,331,265 shares Shares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
Frazier Life Sciences X prefunded warrants 1,458,294 shares Shares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
Frazier Life Sciences XI prefunded warrants 2,459,389 shares Shares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
prefunded warrants financial
"certain prefunded warrants to acquire shares of Common Stock"
Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.
beneficial ownership limitations regulatory
"exercise of which is subject to certain beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
shared dispositive power regulatory
"share voting and investment power over the shares of Common Stock held by FLS X"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TRVI shares does Frazier Life Sciences Public Fund report?

Frazier Life Sciences Public Fund, L.P. reports beneficial ownership of 7,883,659 Trevi Therapeutics common shares, representing 5.5% based on 142,475,841 shares outstanding as of July 31, 2026. It reports shared voting and dispositive power over those shares.

What prefunded warrants do the Frazier funds hold in TRVI?

Frazier Life Sciences Public Fund, L.P. holds prefunded warrants to purchase 10,331,265 shares; Frazier Life Sciences X, L.P. holds warrants to purchase 1,458,294 shares; and Frazier Life Sciences XI, L.P. holds warrants to purchase 2,459,389 shares. Each position may not be exercised if the exercise would result in beneficial ownership above 9.99% of shares outstanding immediately after exercise, including shares held with affiliates or persons acting as a group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





89532M101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G



Frazier Life Sciences Public Fund, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:11/16/2026
FHMLSP, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:11/16/2026
FHMLSP, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:11/16/2026
Frazier Life Sciences X, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:11/16/2026
FHMLS X, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:11/16/2026
FHMLS X, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:11/16/2026
Frazier Life Sciences XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:11/16/2026
FHMLS XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:11/16/2026
FHMLS XI, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:11/16/2026
James N. Topper
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney
Date:11/16/2026
Patrick J. Heron
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025)

Keep reading